

FIRST ANNOUNCEMENT

Transforming drug development

BBS Spring Seminar

May 24, 2022 from 14:00-17:15

Roche Auditorium, Grenzacherstrasse 124, Bau 71

The current drug development model is confronted by major challenges including rising clinical trial costs, a tougher competitive landscape, and growing pressure from payers. Consequently, there is an increasing awareness that drug development must be fundamentally updated to meet these challenges.

This seminar first addresses why transformation is needed from a pharma development and from an investor perspective. It then discusses three areas of innovation where biostatisticians can play a major role. The seminar will conclude with a panel discussion with all speakers and members from pharma and regulatory authorities.

Organizing committee: Achim Güttner, Hans Ulrich Burger, Lilla Di Scala, Marcel Wolbers

Agenda

- | | |
|----------------------|---|
| 14:00 – 14:10 | Welcome , Uli Burger, BBS President |
| 14:10 – 15:00 | Why is transformation of drug development needed?
Chair: Achim Güttner, Novartis
Pharma development perspective: Guy Braunstein, Pierre Verweij, Idorsia
Investor perspective: Pavithra Rallapalli, Colin Terry, Deloitte |
| 15:00 – 15:30 | Coffee break |
| 15:30 – 16:30 | Areas of innovation in drug development: case studies and future vision
Chair: Fred Sorenson, Xcenda
Real-world data: Dominik Heinzmann, Novo Nordisk
External controls : Lisa Hampson, Sebastian Weber, Novartis
Digital biomarkers: Laurent Essioux, Roche |
| 16:30 – 17:15 | Panel discussion
Chair: Marcel Wolbers, Roche
Panel: All speakers, Lorenzo Hess, Swissmedic, and Frank Bretz, Novartis |
| 17:15 | Closure of main meeting |
| 17:20 – 17:45 | BBS general assembly |



Hybrid event:

In person at Auditorium
Grenzacherstrasse- Bau 71,
Roche, Basel & virtual
attendance

Participation is free of charge

Registration

Please register via the
following
link

Map for Roche Areal, Grenzacherstrasse 124:

